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Abstract
Purpose Given the potential interference between treatment
for metastatic colorectal cancer (mCRC) and surgical
procedures, we sought to determine the prevalence of
major surgery following mCRC diagnosis in clinical
practice.
Methods This cohort study used physician-surveyed data
from the LifeLink™ Oncology Analyzer database for
mCRC patients in five European countries (France,
Germany, Italy, Spain, and the United Kingdom [UK]). All
patients aged ≥21 years at mCRC diagnosis and with data
collected during 2009 were included. Major surgical proce-
dures were examined descriptively by the purpose and
location of surgery.
Results The study sample included 3,249 mCRC patients;
515, 862, 656, 649, and 567 were from France, Germany,
Italy, Spain, and the UK, respectively. Following mCRC
diagnosis, at least one major surgical procedure for any
purpose was seen in 30.5% (UK), 35.2% (Germany), 35.6%
(Spain), 36.3% (France), and 38.4% (Italy) of patients, with
a mean of 1.3 (UK) to 1.6 (France) procedures. The rate of
major surgery for curative purposes was the highest in Italy
(13.4%), followed by France (12.8%), Spain (10.3%), and
Germany (9.2%); the lowest was in the UK (7.2%). Major
surgery performed on the primary tumor (12.4–27.1% of
patients, depending on the country) and metastasis (6.4–
14.6%) made up the majority of all surgical procedures.
Conclusions Major surgery is highly prevalent following
mCRC diagnosis, suggesting an important role in meeting
the goals of mCRC treatment. The role of pharmacological
treatment options and their potential to interfere with both
surgery use and surgical outcomes should be considered
when evaluating mCRC treatment strategies.
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Introduction
During the last decade, numerous advancements have been
made in the treatment of metastatic colorectal cancer
(mCRC), including the development of new chemotherapy
regimens, the introduction of monoclonal antibodies
(mAbs) targeting vascular endothelial growth factor
(VEGF) or epidermal growth factor receptor (EGFR), and
the optimization of their usage [1–5]. With the exception of
the United Kingdom (UK), recent literature has shown that
nearly half of patients with mCRC in Europe receive mAb
therapy as part of their pharmacological treatment for
mCRC [6]. Although mAbs have improved outcomes, they
have severe treatment-related toxicities. However, anti-
VEGF and anti-EGFR agents have distinct safety profiles
[1–5]. Wound-healing complications, a severe adverse
event associated with anti-VEGF treatment, interfere with
surgical procedures in patients with mCRC [1, 7–10;
Avastin SmPC; Avastin PI]. In order to avoid an increased
risk of wound-healing complications, the European Society
for Medical Oncology (ESMO) clinical guidelines recom-
mend that patients should wait at least 5–8 weeks after
cessation of anti-VEGF therapy, specifically bevacizumab,
to have surgery and that bevacizumab should not be
reinitiated for at least 28 days after surgical operations
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[10]. Consequently, the potential impact of bevacizumab
with regard to wound healing should be considered in all
patients undergoing surgical procedures [8].
There are multiple reasons for which patients with
mCRC may undergo surgery. Resection with curative intent
is possible in some patients with mCRC, of whom
approximately 30% remain alive 5 years post-resection
[11, 12]. Of particular note is that the ESMO clinical
guidelines for advanced CRC indicate that surgical resec-
tion should be considered for solitary or confined liver
metastases and for resectable lung metastases [10]. As
pharmacological therapy may achieve sufficient shrinkage
of tumors to allow surgical resection in some patients who
were previously considered unresectable (conversion ther-
apy), the National Comprehensive Cancer Network guide-
lines recommend that eligibility for conversion therapy
should be re-evaluated every 2 months [13]. Other cancer-
related reasons for surgical procedures also recommended
by guidelines include biopsy and surgery in patients with a
risk of obstruction or bleeding [13]. While surgery is an
important component in the treatment of mCRC, patients
with mCRC may also undergo surgical procedures unrelat-
ed to their cancer, such as bone fracture repair, and surgery
for comorbidities such as heart disease. Given the lack of
data quantifying the prevalence of surgery following
mCRC diagnosis, this study was designed to evaluate the
prevalence of major surgery in patients with mCRC in
clinical practice in five European countries.
Methods
Data Source and Elements Extracted
We analyzed data contained within the LifeLink™ Oncol-
ogy Analyzer™ database from IMS Consulting Group. This
database included information on patients with cancer of all
types and stages treated by a panel of nearly 2,300
physicians at hospitals, private clinics, and other cancer
care centers across Europe, USA, and Japan. Quarterly,
physicians were asked to provide case histories for the last
five to 25 patients whom they have seen. They were
requested not to provide the same patient’s details twice in
any 12-month period. The records included full treatment
history from diagnosis to current treatment, including all
major surgical procedures.
European data were collected using a paper-based
medical record abstraction form which the physician
completes for each patient [14]. Information for all patients
from France, Germany, Italy, Spain, and the UK with stage
IV CRC (mCRC), aged ≥21 years at mCRC diagnosis, and
with data collected during the year 2009, were identified
from the database. Data relating to demographic character-
istics (age, gender, weight, height, and specialty of treating
physician), use of chemotherapeutic and monoclonal
antibody therapy, and major surgical procedures performed
after patients were diagnosed with mCRC were extracted
from the database. Major surgical procedures were catego-
rized by the purpose of surgery (curative, palliative, or
diagnostic) and also examined by location of surgery
(primary tumor, metastases, or other locations). Both
prevalence of major surgery and number of surgical
procedures were evaluated.
Statistical Analysis
Surgery patterns were analyzed descriptively overall and
also by subcategories: major surgery performed for
curative, palliative, or diagnostic purposes and major
surgery for the primary tumor, metastasis, or at other
locations. Mean, standard deviation (SD), and median
values were calculated for continuous variables, while




The study sample included 3,249 patients with mCRC
(61% male, median age category 61–70 years), of whom
515, 862, 656, 649, and 567 were from France, Germany,
Italy, Spain, and the UK, respectively (Table 1). Across all
countries, most patients were treated by medical oncolo-
gists (range 58.7% [UK] to 86.8% [Spain]), although many
other specialties were involved in mCRC treatment. In
particular, radiologists in the UK were responsible for the
treatment of 35.5% of patients, in contrast to all other
European countries (range 2–3%). Gastroenterologists
treated 22.9% of patients in France and 11.0% of patients
in Germany, while general surgeons treated 6.5–11.9% of
patients, depending on the country.
Surgical Procedures in Patients with mCRC
Overall Extent of Surgical Procedures
The percentage of patients that underwent at least one
major surgical procedure for any purpose as part of
treatment for or while being treated for mCRC was 30.5%
(UK), 35.2% (Germany), 35.6% (Spain), 36.3% (France),
and 38.4% (Italy). Following mCRC diagnosis, patients
were subject to a mean of 1.3 major surgical procedures in
the UK (SD 0.7) and Spain (SD 0.6), 1.5 in Italy (SD 0.7)
and Germany (SD 0.8), and 1.6 in France (SD 0.8).
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Surgical Procedures by Purpose
The distribution of patients by major surgical procedure
categories in each country is shown in Fig. 1. Between
5.7% (Spain) and 14.1% (UK) of patients (7.3% [Italy],
8.4% [Germany], and 11.5% [France]) received major
surgery for diagnostic purposes. The mean number of
major surgeries per person for diagnostic purposes was
approximately 1.1 across all five European countries (SD
range 0.2–0.4). Major surgery for palliative purposes was
performed in 10.8% of patients in the UK, 15.7% in France,
19.4% in Italy, and 20.5% in Germany and Spain. Finally,
the rate of major surgery for curative purposes was the
highest in Italy (13.4%), followed by France (12.8%), Spain
(10.3%), and Germany (9.2%); the lowest was in the UK
(7.2%). The mean total number of major surgical proce-
dures per patient for curative purposes ranged from 1.3
(Germany and Spain) to 1.6 (France).
Table 1 Demographic and patient characteristics by country
France Germany Italy Spain UK
(N=515) (N=862) (N=656) (N=649) (N=567)
Age group, years (% patients)
21–30 1 0 1 0 1
31–40 2 1 2 1 2
41–50 4 6 8 8 9
51–60 20 20 24 24 20
61–70 36 40 41 30 33
71–80 24 25 20 24 26
>80 10 7 4 11 7
Not specified 3 1 2 2 3
Gender (% patients)
Male 59 61 64 62 61
Height, cm
Mean (SD) 169 (9) 172 (9) 169 (9) 166 (9) 169 (9)
Median 170 172 170 167 170
Weight, kg
Mean (SD) 70 (13) 75 (14) 70 (13) 70 (12) 74 (14)
Median 70 75 70 69 72
Body mass index (BMI)
Mean (SD) 25 (4) 25 (4) 25 (4) 25 (4) 25.8 (5)
Median 24 25 24 25 25
Body surface area (BSA)
Mean (SD) 1.8 (0.2) 1.9 (0.2) 1.8 (0.2) 1.8 (0.6) 1.9 (1.0)
Median 2 2 2 2 2
Treating physician specialty (%)
Cardiothoracic surgery 0 0.0 0.8 0.0 0.0
Ear, nose, and throat 0 0.0 0.0 0.6 0.0
Gastroenterology 22.9 11.0 0.3 0.0 1.8
General medicine 1.9 3.5 0.0 0.0 0.0
General surgery 8.9 6.5 11.9 10.3 3.0
Gynecology 0.0 0.0 0.0 0.0 0.7
Hematology 3.5 3.1 0.3 0.3 0.2
Medical oncology 59.0 61.6 83.7 86.8 58.7
Onco-hematology 0.0 11.7 0.0 0.0 0.0
Radiotherapy 3.3 2.4 2.0 2.0 35.5
Thoracic/chest medicine 0.2 0.1 0.3 0.0 0.0
Urology 0.0 0.0 0.2 0.0 0.0
Not specified 0.2 0.0 0.6 0.0 0.2
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Surgical Procedures by Location
The distribution of major surgical procedures catego-
rized by the location of surgery (primary tumors,
metastases, and other locations/reasons) in each of the
five countries is shown in Fig. 2. Approximately 20% of
patients from each country, except the UK (12.4%), had at
least one major surgical procedure for primary tumor
excision after mCRC diagnosis with a mean of approxi-
mately one primary tumor surgery per patient (mean range
1.0–1.1). Italy had the highest number of patients who
underwent major surgery for metastasis (14.6%), followed
by Spain (9.2%), France (8.9%), and Germany (8.5%); it
was lowest in the UK (6.4%). The major surgery for
metastasis by the organ site of metastasis was mainly on
the liver though some variations existed across countries.
Among patients who had major surgery for metastasis, the
percentage of patients who had surgery on the liver was
86.1% in the UK, 80.8% in Germany, 76.1% in Italy,
68.3% in Spain, and 58.7% in France. Major surgery at
other locations was reported in 4.3% (Spain) to 8.8%
(Germany) of patients with a mean of approximately one
surgery per patient (mean range 1.0–1.2).
Discussion
This study assessed the extent to which patients with
mCRC underwent major surgical procedures following
diagnosis of mCRC in clinical practice in five European
countries. Our analyses indicate that major surgery occurs
frequently, with 30–38% of patients undergoing at least one
major surgical procedure following diagnosis of mCRC.
Although there were substantial differences among
countries, major surgery for curative, palliative, and
diagnostic purposes were common across all five European
countries. Major surgery performed on the primary tumor
and at sites of metastasis made up the majority of all
surgical procedures, implying that surgery played a consid-
erable role in the treatment of mCRC.
The country-specific differences in major surgery rates
may be explained, at least in part, by the availability of
advanced treatment options and difference in clinicians’
attitudes and approaches to surgery for mCRC. Addition-
ally, national guidelines for the treatment of mCRC,
developed and based on treatment options available in the
country, exist in France, Germany, Italy, and the UK [15–
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Fig. 1 Surgery by purpose:
patients with at least one































Percentage of patients with at least one surgery for the primary tumor
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Fig. 2 Surgery by location:
patients with at least one
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ing the use of surgery, leading to subsequent differences in
the number and types of surgical procedures reported.
Surgery rates may be influenced by the availability of
appropriately trained surgeons. Additionally, country-
specific differences may be attributable to differences in
access to newer treatment options. For example, the UK
National Institute for Health and Clinical Excellence
(NICE) does not recommend the use of bevacizumab in
mCRC and cetuximab has only recently been recommended
for restricted use in the UK [19–21]. Since there is some
evidence that adding an mAb to cytotoxic chemotherapy
may increase resection rates compared with the use of
cytotoxic chemotherapy alone [22], this may partially
explain the relatively lower rates of surgical procedures
for metastases and curative purposes in the UK.
The ESMO guidelines for treatment of advanced
CRC recommend that resection of metastases should
be performed as soon as the metastases become
resectable, since unnecessary prolonged administration
of chemotherapy may lead to higher postoperative
morbidity [10]. The potential requirement for surgery
should therefore be an important consideration when
selecting treatment for mCRC. With advances in systemic
therapy and surgical techniques, it is likely that the
number of surgical procedures will increase further during
treatment of mCRC.
There are some limitations to our analyses. As survey
data were used in this study, sample selection bias could
occur. However, the survey contains a random sample
of oncology patients, which should reduce the chance
for selection bias. The study also used data from five
European countries and the findings may not be
generalizable to other countries. Finally, the observation
period after mCRC diagnosis might be truncated before
death, especially for newly diagnosed patients; thus, the
prevalence of major surgeries from this study could be
underestimated.
In summary, this study showed that major surgery is highly
prevalent following mCRC diagnosis, suggesting that surgery
plays an important role in meeting the goals of mCRC
treatment. The role of pharmacological treatment options and
their potential to interfere with both surgery use and surgical
outcomes should be considered when evaluating mCRC
treatment strategies.
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